GET DAILY SIGNALSTG Therapeutics (TGTX): Can the Stock Reach the $79 Analyst Target?
Key Takeaways
- The central target of $79 is the arithmetic mean of the five verified analyst price targets that sit above the current share price, after the overall mean of all seven valid targets (about $65) fell within 10% of the recent price.
- At a recent price of roughly $59.83, reaching $79 implies about 32% upside — a substantial move.
- Across all seven verified targets, the mean is about $65, with a wide low-to-high range of $21 to $86.
- The strongest supports are Briumvi revenue growth, profitability, and the potential for a subcutaneous version of the drug.
- The biggest risks are a full-year revenue guide that landed below consensus and competition in the CD20 multiple sclerosis market.
- For deeper coverage, visit Major News, Today's Price Move, Forecast, and Earnings pages for this ticker.
- Explore Trending AI Robots to see AI-driven strategies monitoring stocks and ETFs in real time.
Analyst Price Targets and Consensus View
Seven current analyst price targets were reviewed for TGTX, spanning a wide range from $21 to $86. The bull camp is led by B. Riley Securities at $86 (September 2, 2026), Jefferies at $83, H.C. Wainwright at $78, TD Cowen at $75, and J.P. Morgan at $72. Goldman Sachs sits in the middle at $41, while Bank of America Securities remains the lone bear at $21 with an Underperform rating.
The arithmetic mean of all seven valid targets is about $65 — only roughly 9% above the recent price, which fails the minimum-distance threshold used here. As a result, the central target is calculated from the five targets that sit above the current price ($72, $75, $78, $83, and $86), which average $78.8, rounded to $79. For context, the overall mean of all valid targets remains about $65, and the full range is $21 to $86 — a wide spread that reflects genuine disagreement about Briumvi's growth runway and competitive threats.
Recent revisions have leaned bullish: B. Riley lifted its target from $55 to $86 in late July 2026, and J.P. Morgan raised its target from $65 to $72 in early August. Bank of America nudged its target higher from $17 to $20 to $21 but kept its Underperform stance. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
Shares recently closed near $59.83, giving the stock a market capitalization of roughly $9.2 billion. Reaching $79 would require about a 32% gain — a substantial move by any measure. The stock's 52-week range of $26.76 to $63.60 shows how far it has already rallied, up roughly 97% over the past 12 months.
The path toward $79 would likely depend on continued Briumvi prescription growth, expanding profitability, and progress on a subcutaneous formulation that could broaden the drug's addressable market. Third-quarter 2026 revenue of $259.94 million beat the $245.47 million consensus, though EPS of $0.35 missed estimates by $0.02. From what I see, execution on these fronts will be key.
What Could Support a Move Toward the Target
- Briumvi momentum: The company's lead therapy continues to gain share among high-efficacy IV multiple sclerosis treatments.
- Profitability: TGTX has turned a corner into positive earnings, strengthening the case for a higher valuation multiple.
- Subcutaneous expansion: A potential subcutaneous Briumvi could expand the market opportunity, a theme cited by several bullish analysts.
- Upward revisions: Multiple firms raised targets through mid-2026, signaling improving fundamental confidence.
What Could Prevent the Target From Being Reached
- Guidance shortfall: Full-year 2026 revenue guidance of $915 million to $920 million came in below the roughly $960 million consensus.
- Competition: Rival CD20 therapies and other high-efficacy MS drugs could pressure Briumvi's growth.
- Bearish dissent: Bank of America's $21 target reflects skepticism that the cash inflection can be sustained against competitive pressure.
- Valuation: A P/E ratio in the low-20s leaves limited room for disappointment without earnings growth.
Technical Levels and Market Structure
The 52-week high near $63.60 stands as the nearest resistance level that TGTX would need to clear on any sustained move higher. Beyond that, round-number levels at $70 and $75 could act as psychological markers before the $79 target area. On the downside, the $55–$57 zone and the $41–$50 band represent deeper support levels, with the 52-week low of $26.76 far below. I’m watching this closely for any breakouts.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of about 12 months, though individual analysts apply their own timelines. Investors should watch upcoming quarterly results and any revision to full-year guidance, analyst target changes, subcutaneous Briumvi clinical or regulatory milestones, and competitive launches in the MS space. These catalysts will shape whether the market outlook shifts the stock toward — or away from — the $79 level.
Using Tickeron AI Tools in My Research
In my own work, I rely on Tickeron’s AI Daily Buy/Sell Signals to track names like TGTX alongside broader market moves. The platform applies AI to monitor thousands of stocks and ETFs in real time, helping identify potential shifts in technical behavior and trends without replacing personal judgment. It serves as one practical input when evaluating opportunities in the biopharma space.
Final Assessment
The $79 central target reflects the average of the five analyst price targets that sit above the current share price, given that the overall mean of all seven targets (about $65) was too close to the recent price to be meaningful. Reaching $79 would require a substantial gain of roughly 32%, and the wide $21-to-$86 analyst range underscores how sharply views diverge. Bullish analysts emphasize Briumvi's growth and the subcutaneous opportunity, while bears point to a guidance shortfall and intensifying competition. Whether TGTX can bridge that gap will hinge on execution, revenue trajectory, and upcoming catalysts — none of which can be predicted with certainty.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TGTX in upward trend: 10-day moving average crossed above 50-day moving average on October 30, 2026
The 10-day moving average for TGTX crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on TGTX as a result. In 67 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for TGTX just turned positive on October 27, 2026. Looking at past instances where TGTX's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.
TGTX moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where TGTX advanced for three days, in 253 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 177 of 226 cases where TGTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The 10-day RSI Indicator for TGTX moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 48 similar instances where the indicator moved out of overbought territory. In 35 of the 48 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 62 cases where TGTX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TGTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
TGTX broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. TGTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 47 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.159) is normal, around the industry mean (3.498). P/E Ratio (19.551) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (11.136) is also within normal values, averaging (440.869).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company
Industry Biotechnology
Advertisement